Developing first-in-class cardiovascular biopharmaceuticals that target natural repair pathways.

Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating from the laboratory of cofounder Marc Penn, M.D., Ph.D., FACC and the technologies he discovered and developed at the Cleveland Clinic. Juventas is currently planning Phase 2b studies in advanced ischemic heart failure and late-stage peripheral artery disease.